Receptor News and Research

RSS

New study pinpoints key source of T cell "exhaustion"

Custom-made to attack cancer cells, CAR T-cell therapies have opened a new era in the treatment of human cancers, particularly, in hematologic malignancies.

21 Mar 2023

T cell-driven changes in the gut may affect brain function associated with depression

In experiments with mice and humans, a team led by Johns Hopkins Medicine researchers says it has identified a particular intestinal immune cell that impacts the gut microbiome, which in turn may affect brain functions linked to stress-induced disorders such as depression.

21 Mar 2023

Uncovering the role of the third intracellular loop in the GPCR’s signaling mechanism

Over a one-third of FDA-approved drugs tend to function by targeting a G protein-coupled receptor, or so-called GPCR. The human body consists of over 800 kinds of GPCRs that offer cells with data concerning the external surrounding to calibrate responses.

20 Mar 2023

Macrophages likely to be a potential target for ER+ breast cancer

Most immunotherapies that aim to increase T cell activity are ineffective in treating estrogen receptor-positive (ER+) breast cancer. A new study of invasive ER+ breast cancers led by researchers at the University of Pittsburgh School of Medicine implies that targeting a different type of immune cell called macrophages may be a more effective approach.

From University of Pittsburgh 20 Mar 2023

Researchers uncover the role of third intracellular loop in GPCR's signaling mechanism

More than a third of FDA-approved drugs work by targeting a G protein-coupled receptor, or GPCR. The human body has more than 800 types of GPCRs that provide cells with information about the external environment to calibrate responses.

20 Mar 2023

Immune landscape in invasive ER+ breast cancers reveals a macrophage-driven microenvironment

Most immunotherapies, which aim to boost T cell activity, work poorly in treating estrogen receptor-positive (ER+) breast cancer.

20 Mar 2023

New combination therapy regimen may reduce prostate cancer progression or death by 37%

TALAPRO-2, a study led by Neeraj Agarwal, MD, FASCO, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progression or death by 37%.

20 Mar 2023

First molecular images of olfaction sets the stage to create novel smells

Breaking a longstanding impasse in our understanding of olfaction, scientists at UC San Francisco (UCSF) have created the first molecular-level, 3D picture of how an odor molecule activates a human odorant receptor, a crucial step in deciphering the sense of smell.

16 Mar 2023

Gut microbiome may modulate the efficacy of CAR-T cell cancer immunotherapy

Scientists from German Cancer Research Center (DKFZ), together with colleagues from Germany, Israel, and the USA, have found that the gut microbiome may modulate the efficacy of CAR-T cellular immunotherapy CAR-T cells in patients with B cell lymphomas.

14 Mar 2023

New framework to identify possible viral hazards to human health

The majority of what scientists know about viruses in animals comes from the list of nucleotides that constitute their genomic sequence, which, although useful, provides relatively few signals about a virus’ propensity to infect people.

14 Mar 2023

New perspective on how immune cells perceive viruses and other threats

A textbook chapter on the immune system may need to be revised as a result of a new study from Aarhus University.

14 Mar 2023

Effective backup mechanism ensures efficient antimicrobial responses in humans

In the human body, virus particles are identified by pattern recognition receptors (PRRs) either within or on the cell surface. When a receptor is activated, a signaling cascade is initiated, which results in the production and release of signaling molecules like interferons and cytokines.

14 Mar 2023

Understanding the relationship between gut microbiome and CAR T-cell therapy response

Microorganisms live in or on almost every part of the human body and play an important role in the regulation of normal human processes. As a result, changes in the number or type of microorganisms, also known as the microbiome, can contribute to disease and altered responses to therapy, including cancer treatment.

14 Mar 2023

New class of oral drugs inhibits a diverse range of SARS-CoV-2 strains

The constant evolution of new COVID-19 variants makes it critical for clinicians to have multiple therapies in their arsenal for treating drug-resistant infections. Researchers have now discovered that a new class of oral drugs that acts directly on human cells can inhibit a diverse range of pathogenic SARS-CoV-2 strains.

13 Mar 2023

Novel model tracks hippocampal synaptic plasticity to reveal molecular mechanisms

The accumulation of amyloid beta proteins, which encourage synaptic malfunction, causes cognitive decline in Alzheimer’s disease (AD), according to scientific evidence.

10 Mar 2023

Study links neutral maternal behavior toward infants with epigenetic change in children

Adding evidence to the importance of early development, a new study links neutral maternal behavior toward infants with an epigenetic change in children related to stress response.

3 Mar 2023

Stress response in mom leads to epigenetic change in children

Adding evidence to the importance of early development, a new study links neutral maternal behavior toward infants with an epigenetic change in children related to stress response.

2 Mar 2023

Novel framework provides solutions to evade detoxification networks

Scientists at St. Jude Children's Research Hospital have demonstrated how drug makers can avoid two key problems: toxicity and resistance. The researchers made slight changes to a small molecule to reduce its metabolism and elimination by the cellular detoxification network regulated by the pregnane X receptor (PXR). This research provides a framework to develop solutions to the long-standing issue of how to evade detoxification networks using medicinal chemistry. The findings were published today in Proceedings of the National Academy of Sciences.

1 Mar 2023

New model, C. elegans, helps pursue research on Parkinson's disease

A tiny worm called the C. elegans is enabling scientists to explore the emerging theory that Parkinson's disease starts in the gut.

1 Mar 2023

Artificial BBB model can help determine how well antibody-based therapies can enter the brain

A research group at Uppsala University has developed a simple and effective artificial blood-brain barrier model that can be used to determine how well antibody-based therapies can enter the brain.

27 Feb 2023

Receptor News and Research

New study pinpoints key source of T cell "exhaustion"

T cell-driven changes in the gut may affect brain function associated with depression

Uncovering the role of the third intracellular loop in the GPCR’s signaling mechanism

Macrophages likely to be a potential target for ER+ breast cancer

Researchers uncover the role of third intracellular loop in GPCR's signaling mechanism

Immune landscape in invasive ER+ breast cancers reveals a macrophage-driven microenvironment

New combination therapy regimen may reduce prostate cancer progression or death by 37%

First molecular images of olfaction sets the stage to create novel smells

Gut microbiome may modulate the efficacy of CAR-T cell cancer immunotherapy

New framework to identify possible viral hazards to human health

New perspective on how immune cells perceive viruses and other threats

Effective backup mechanism ensures efficient antimicrobial responses in humans

Understanding the relationship between gut microbiome and CAR T-cell therapy response

New class of oral drugs inhibits a diverse range of SARS-CoV-2 strains

Novel model tracks hippocampal synaptic plasticity to reveal molecular mechanisms

Study links neutral maternal behavior toward infants with epigenetic change in children

Stress response in mom leads to epigenetic change in children

Novel framework provides solutions to evade detoxification networks

New model, C. elegans, helps pursue research on Parkinson's disease

Artificial BBB model can help determine how well antibody-based therapies can enter the brain

Driving Support for Pharmaceutical Testing Through Continuous Innovation

From Memory to Metaplasticity: Unraveling the Brain's Secrets

Revolutionizing Mass Spectrometry: A Deep Dive into Plasmion’s SICRIT® Technology

Latest in Genomics